Ethionamide

Antimycobacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Ethionamide is an ofm drug in the Antimycobacterial class catalogued in DrugCentral. It was first approved by the FDA in 1965. DrugCentral lists 3 molecular targets, including PPO2, katG and inhA. Recorded indications include Acute tuberculosis, Pulmonary Mycobacterium avium complex infection and Pulmonary tuberculosis.

• Approval status: ofm (first approved 1965 by the FDA).
• Drug class: Antimycobacterial.
• Molecular targets: PPO2, katG and inhA (3 listed in DrugCentral).
• Indications: Acute tuberculosis, Pulmonary Mycobacterium avium complex infection and Pulmonary tuberculosis.
• ATC code: J04AD03 (Thiocarbamide derivatives).
• Molecular formula: C8H10N2S; molecular weight 166.25 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Acute tuberculosis
• Pulmonary Mycobacterium avium complex infection
• Pulmonary tuberculosis

Off-label uses (3)

• Atypical mycobacterial infection
• Leprosy
• Tuberculosis of meninges

Contraindications (5)

• Alcoholism
• Diabetes mellitus
• Disease of liver
• Hepatic failure
• Hypothyroidism

Mechanism & targets

• Established pharmacologic class: Antimycobacterial

Molecular targets (3)

Target	Gene	Action	Activity
Polyphenol oxidase 2	PPO2	unknown	IC50 5.40
Catalase-peroxidase	katG	unknown	—
Enoyl-[acyl-carrier-protein] reductase [NADH]	inhA	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1965-04-30	FDA	—	WYETH PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
J04AD03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Thiocarbamide derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug resistance	446.2
Electrocardiogram QT prolonged	195.2
Neuropathy peripheral	116.9
Drug reaction with eosinophilia and systemic symptoms	107.5
Pathogen resistance	89.5
Urinary tract inflammation	80.5
Tuberculoma of central nervous system	76.9
Anaemia	76.5
Hepatitis cholestatic	60.5
Conductive deafness	55.5
Vomiting	55.4
Treatment failure	48.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ethionamide is on its molecule page.

• Molecular formula: C₈H₁₀N₂S
• Molecular weight: 166.25 g/mol
• CAS number: —
• InChIKey: AEOCXXJPGCBFJA-UHFFFAOYSA-N
• PubChem CID: 2761171

CCC1=CC(=CC=N1)C(N)=S

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ethionamide used for?

DrugCentral lists the following indications for Ethionamide: Acute tuberculosis, Pulmonary Mycobacterium avium complex infection and Pulmonary tuberculosis.

How does Ethionamide work?

Its molecular targets in DrugCentral include PPO2, katG and inhA (inhibitor).

When was Ethionamide first approved?

Ethionamide was first approved by the FDA in 1965.

What drug class does Ethionamide belong to?

Ethionamide is in the Antimycobacterial class.

What is the chemical formula of Ethionamide?

Ethionamide has the molecular formula C8H10N2S and a molecular weight of 166.25 g/mol.

Sources

• DrugCentral drug card 1083 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1441 — compound record and bioactivity
• PubChem CID 2761171 — chemical identifiers
• DrugBank DB00609 — drug record
• FDA UNII OAY8ORS3CQ — substance identity
• DailyMed: FDA labels for Ethionamide — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.